Kusuda M, Haroon N, Nakamura A. Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches. Mod Rheumatol. England; 2022;32(3):484-492.

Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N. Pathogenesis of ankylosing spondylitis — recent advances and future directions. Nat Rev Rheumatol United States. 2017;13:359–67.

CAS  Article  Google Scholar 

Dougados M, Baeten D. Spondyloarthritis Lancet England. 2011;377:2127–37.

Article  Google Scholar 

Nakamura A, Haroon N. Recent updates in the immunopathology of type 3 immunity-mediated enthesitis. CurrRheumatol Rep. United States; 2021;23:31.

Nakamura A, Talukdar A, Nakamura S, Pathan E, Haroon N. Bone formation in axial spondyloarthritis: is disease modification possible? Best Pract Res Clin Rheumatol. Netherlands. 2019;33: 101491.

Google Scholar 

Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med United States. 2015;163:409–16.

Article  Google Scholar 

Kuriya B, Tia V, Luo J, Widdifield J, Vigod S, Haroon N. Acute mental health service use is increased in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study. Therapeutic Advances in Musculoskeletal Disease [Internet]. SAGE Publications; 2020;12:1759720X20921710. Available from: https://doi.org/10.1177/1759720X20921710

Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases [Internet]. 2021;80:1004. Available from: http://ard.bmj.com/content/80/8/1004.abstract

Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. The Lancet [Internet]. Elsevier; 2018;391:2513–24. Available from: https://doi.org/10.1016/S0140-6736(18)31116-4

Wei JC-C, Kim T-H, Kishimoto M, Ogusu N, Jeong H, Kobayashi S, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis. 2021;

ClinicalTrials.gov. A study to evaluate the efficacy and safety of bimekizumab in subjects with active nonradiographic axial spondyloarthritis (BE MOBILE 1). 2021.

Macfarlane GJ, Pathan E, Jones GT, Dean LE. Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford). 2020;59:2481–90.

Article  Google Scholar 

Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18:205–16.

PubMed  Article  Google Scholar 

Kang I, Bucala R. The immunobiology of MIF: function, genetics and prospects for precision medicine. Nat Rev Rheumatol United States. 2019;15:427–37.

Article  Google Scholar 

Greven D, Leng L, Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets England. 2010;14:253–64.

CAS  Article  Google Scholar 

Bae S-C, Lee YH. Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between MIF gene polymorphisms and disease susceptibility: a meta-analysis. Postgrad Med J. 2018;94:109–15.

CAS  PubMed  Article  Google Scholar 

Sreih A, Ezzeddine R, Leng L, LaChance A, Yu G, Mizue Y, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011;63:3942–51.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kim H-R, Park M-K, Cho M-L, Yoon C-H, Lee S-H, Park S-H, et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol. 2007;34:927–36.

CAS  PubMed  Google Scholar 

Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis & Rheumatism [Internet]. John Wiley & Sons, Ltd; 2003;48:1881–9. Available from: https://doi.org/10.1002/art.11165

Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka S, et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem. 2002;277:7865–74.

Hoi AY, Hickey MJ, Hall P, Yamana J, O’Sullivan KM, Santos LL, et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol. 2006;177:5687–96.

CAS  PubMed  Article  Google Scholar 

Gürel Ç, İnanır A, Nursal AF, Tekcan A, Rüstemoğlu A, Yigit S. Evaluation of MIF -173 G/C polymorphism in Turkish patients with ankylosing spondylitis. Balkan Med J. 2016;33:614–9.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol. 2010;20:34–9.

CAS  PubMed  Article  Google Scholar 

Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J, et al. Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis and Rheumatology. 2017;69(9):1796–806.

CAS  PubMed  Article  Google Scholar 

Nakamura A, Zeng F, Nakamura S, Reid KT, Gracey E, Lim M, et al. Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease. Sci Transl Med. 2021;13:eabg1210.

Rahman MA, Thomas R. The SKG model of spondyloarthritis. Best Pract Res Clin Rheumatol Netherlands. 2017;31:895–909.

Article  Google Scholar 

Rich AR, Lewis MR. The nature of allergy in tuberculosis at revealed by tissue culture studies. Bull Johns Hopkins Hosp. 1932;50:115–31.

Google Scholar 

Goldberg LS, Louie JS, Baker MH. Inhibition of macrophage migration: a test system using human monocytes. J Immunol. 1971;107:906–9.

CAS  PubMed  Google Scholar 

Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A. 2011;108:E577–85.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tilstam PV, Schulte W, Holowka T, Kim B-S, Nouws J, Sauler M, et al. MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model. J Clin Invest. 2021;131(23):e127171. https://doi.org/10.1172/JCI127171.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Donn R, Alourfi Z, de Benedetti F, Meazza C, Zeggini E, Lunt M, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2402–9.

CAS  PubMed  Article  Google Scholar 

Wu S-P, Leng L, Feng Z, Liu N, Zhao H, McDonald C, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006;54:3661–9.

CAS  PubMed  Article  Google Scholar 

Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hernández RE, Palafox-Sánchez CA, Padilla-Gutiérrez JR, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013;61:759–65.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3:170–6.

CAS  PubMed  Article  Google Scholar 

Wang F-F, Zhu L-A, Zou Y-Q, Zheng H, Wilson A, Yang C-D, et al. New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14:R103.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Eder L, Chandran V, Ueng J, Bhella S, Lee K-A, Rahman P, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford). 2010;49:1367–73.

Article  Google Scholar 

Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal England. 2019;57:76–88.

CAS  Article  Google Scholar 

Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587–96.

CAS  PubMed  Article  Google Scholar 

De R, Sarkar S, Mazumder S, Debsharma S, Siddiqui AA, Saha SJ, et al. Macrophage migration inhibitory factor regulates mitochondrial dynamics and cell growth of human cancer cell lines through CD74-NF-κB signaling. J Biol Chem. 2018;293:19740–60.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Onodera S, Tanji H, Suzuki K, Kaneda K, Mizue Y, Sagawa A, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine. 1999;11:163–7.

CAS  PubMed  Article  Google Scholar 

Meazza C, Travaglino P, Pignatti P, Magni-Manzoni S, Ravelli A, Martini A, et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:232–7.

PubMed  Article  Google Scholar 

de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001;2:1061–6.

PubMed  Article  CAS  Google Scholar 

Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol. 2010;20:34–9.

CAS  PubMed  Article  Google Scholar 

Park M-C, Kwon OC, Lee S-W, Song JJ, Park Y-B. MiR-451 suppresses inflammatory responses in ankylosing spondylitis by targeting macrophage migration inhibitory factor. Clin Exp Rheumatol. 2020;38(2):275–81.

PubMed  Article  Google Scholar 

Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis England. 2014;73:1211–4.

CAS  Article  Google Scholar 

Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis England. 2014;73:1079–82.

CAS  Article  Google Scholar 

Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, et al. Sensitivity and specificity of autoantibodies against CD74 in nonradiographic axial spondyloarthritis. Arthritis Rheumatol United States. 2019;71:729–35.